Omar F Jimenez, MD | |
2 W 42nd St Ste 2100, Rwpc Neurosurgery, Scottsbluff, NE 69361-4669 | |
(308) 630-1947 | |
(308) 630-1439 |
Full Name | Omar F Jimenez |
---|---|
Gender | Male |
Speciality | Neurosurgery |
Experience | 32 Years |
Location | 2 W 42nd St Ste 2100, Scottsbluff, Nebraska |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1154351930 | NPI | - | NPPES |
10025698000 | Medicaid | NE |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207T00000X | Neurological Surgery | 24111 (Nebraska) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Regional West Medical Center | Scottsbluff, NE | Hospital |
Community Hospital | Torrington, WY | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Regional West Physicians Clinic | 2062301609 | 114 |
News Archive
Of the more than 23,000 genes in the human genome, only a handful assume a very central role in signal transduction and growth regulation. Of these, the three genes encoding RAS proteins are particularly important, as they are found mutated in over 25% of human cancers.
In new results from the VALUE trial that pitted the drug valsartan against another blood pressure drug, amlodipine, the patients taking valsartan were found to have a 23 percent lower risk of developing diabetes during the four or more years of the study.
Olodaterol is a long-acting beta2-agonist (LABA) bronchodilator delivered via the Respimat® inhaler. It is being investigated as a once daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
It is necessary to develop additional COVID-19 vaccines, as different vaccine approaches have their advantages and disadvantages and may work synergistically.
› Verified 6 days ago
Entity Name | Regional West Physicians Clinic |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1306910534 PECOS PAC ID: 2062301609 Enrollment ID: O20040315001274 |
News Archive
Of the more than 23,000 genes in the human genome, only a handful assume a very central role in signal transduction and growth regulation. Of these, the three genes encoding RAS proteins are particularly important, as they are found mutated in over 25% of human cancers.
In new results from the VALUE trial that pitted the drug valsartan against another blood pressure drug, amlodipine, the patients taking valsartan were found to have a 23 percent lower risk of developing diabetes during the four or more years of the study.
Olodaterol is a long-acting beta2-agonist (LABA) bronchodilator delivered via the Respimat® inhaler. It is being investigated as a once daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
It is necessary to develop additional COVID-19 vaccines, as different vaccine approaches have their advantages and disadvantages and may work synergistically.
› Verified 6 days ago
Mailing Address | Practice Location Address |
---|---|
Omar F Jimenez, MD 2 W 42nd St Ste 2100, Rwpc - Neurosurgery, Scottsbluff, NE 69361-4669 Ph: (308) 630-1947 | Omar F Jimenez, MD 2 W 42nd St Ste 2100, Rwpc Neurosurgery, Scottsbluff, NE 69361-4669 Ph: (308) 630-1947 |
News Archive
Of the more than 23,000 genes in the human genome, only a handful assume a very central role in signal transduction and growth regulation. Of these, the three genes encoding RAS proteins are particularly important, as they are found mutated in over 25% of human cancers.
In new results from the VALUE trial that pitted the drug valsartan against another blood pressure drug, amlodipine, the patients taking valsartan were found to have a 23 percent lower risk of developing diabetes during the four or more years of the study.
Olodaterol is a long-acting beta2-agonist (LABA) bronchodilator delivered via the Respimat® inhaler. It is being investigated as a once daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
It is necessary to develop additional COVID-19 vaccines, as different vaccine approaches have their advantages and disadvantages and may work synergistically.
› Verified 6 days ago